Erratum: PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer (Nature Medicine (2016) 22 (1303-1313) DOI: 10.1038/nm.4198);PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer

Nature Medicine

Volumn 22, Issue 11, 2016, Pages 1303-1313

  Brasó Maristany, Fara ^a   Filosto, Simone ^a   Catchpole, Steven ^a   Marlow, Rebecca ^a   Quist, Jelmar ^a,b   Francesch Domenech, Erika ^a   Plumb, Darren A ^a   Zakka, Leila ^a   Gazinska, Patrycja ^a   Liccardi, Gianmaria ^c   Meier, Pascal ^c   Gris Oliver, Albert ^d   Cheang, Maggie Chon U ^c   Perdrix Rosell, Anna ^a   Shafat, Manar ^a   Noël, Elodie ^a   Patel, Nirmesh ^a   McEachern, Kristen ^e   Scaltriti, Maurizio ^f   Castel, Pau ^f   Noor, Farzana ^a   Buus, Richard ^c   Mathew, Sumi ^a   Watkins, Johnathan ^a   Serra, Violeta ^d   Marra, Pierfrancesco ^a   Grigoriadis, Anita ^a,b   Tutt, Andrew N ^a,c   more..

^a GUY S HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^e ASTRAZENECA   (United Kingdom)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; CASPASE 3; CASPASE 7; ERIBULIN; MESSENGER RNA; MYC PROTEIN; PACLITAXEL; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN BCL 2; PROTEIN KINASE PIM 1; AZD1208; BCL2 PROTEIN, HUMAN; BIPHENYL DERIVATIVE; MCL1 PROTEIN, HUMAN; MYC PROTEIN, HUMAN; PIM1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN MCL 1; THIAZOLIDINE DERIVATIVE;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; BREAST EPITHELIUM CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL PERMEABILIZATION; CELL POPULATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME INHIBITION; GENE DOSAGE; GENE EXPRESSION; GENOMICS; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RNA INTERFERENCE; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CELL SURVIVAL; COPY NUMBER VARIATION; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; MITOCHONDRION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; MITOCHONDRIA; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NEOPLASM TRANSPLANTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENE PROTEINS C-PIM-1; REAL-TIME POLYMERASE CHAIN REACTION; THIAZOLIDINES; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84992416469     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm0617-788b     Document Type: Erratum

References (65)

1. Reis-Filho, J.S. & Tutt, A.N. Triple-negative tumors: a critical review. Histopathology 52, 108-118 (2008).
2. Symmans, W.F. et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J. Clin. Oncol. 25, 4414-4422 (2007).
3. Masuda, H. et al. Differential response to neoadjuvant chemotherapy among seven triple-negative breast cancer molecular subtypes. Clin. Cancer Res. 19, 5533-5540 (2013).
4. Balko, J.M. et al. Molecular profling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifes actionable therapeutic targets. Cancer Discov. 4, 232-245 (2014).
5. Labisso, W.L. et al. MYC directs transcription of MCL1 and EIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors. Cell Cycle 11, 1593-1602 (2012).
6. Andre, F. et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin. Cancer Res. 15, 441-451 (2009).
7. Bergamaschi, A. et al. Distinct patterns of DNA copy-number alteration are associated with different clinicopathological features and gene expression subtypes of breast cancer. Genes Chromosom. Cancer 45, 1033-1040 (2006).
8. Turner, N. et al. Integrative molecular profling of triple-negative breast cancers identifes amplicon drivers and potential therapeutic targets. Oncogene 29, 2013-2023 (2010).
9. Nawijn, M.C., Alendar, A. & Berns, A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat. Rev. Cancer 11, 23-34 (2011).
10. Wang, J. et al. Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene 29, 2477-2487 (2010).
11. Keeton, E.K. et al. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates effcacy in preclinical models of acute myeloid leukemia. Blood 123, 905-913 (2014).
12. Laird, P.W. et al. In vivo analysis of Pim1 defciency. Nucleic Acids Res. 21, 4750-4755 (1993).
13. Magnuson, N.S., Wang, Z., Ding, G. & Reeves, R. Why target PIM1 for cancer diagnosis and treatment? Future Oncol. 6, 1461-1478 (2010).
14. Narlik-Grassow, M., Blanco-Aparicio, C. & Carnero, A. The PIM family of serine-threonine kinases in cancer. Med. Res. Rev. 34, 136-159 (2014).
15. Aceto, N. et al. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive-feedback signaling loop. Nat. Med. 18, 529-537 (2012).
16. Speers, C. et al. Identifcation of novel kinase targets for the treatment of estrogen-receptor-negative breast cancer. Clin. Cancer Res. 15, 6327-6340 (2009).
17. Lehmann, B.D. et al. Identifcation of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121, 2750-2767 (2011).
18. de Rinaldis, E. et al. Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control. BMC Genomics 14, 643 (2013).
19. Gazinska, P. et al. Comparison of basal-like triple-negative breast cancer defned by morphology, immunohistochemistry and transcriptional profles. Mod. Pathol. 26, 955-966 (2013).
20. The Cancer Genome Atlas. Comprehensive molecular portraits of human breast tumors. Nature 490, 61-70 (2012).
21. Curtis, C. et al. The genomic and transcriptomic architecture of 2, 000 breast tumors reveals novel subgroups. Nature 486, 346-352 (2012).
22. Parker, J.S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160-1167 (2009).
23. Neve, R.M. et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527 (2006).
24. Canbay, E. Erb-B2 homodimerization inhibits MUC1 transcription in cultured human mammary epithelial cells. Cell Biol. Int. 27, 477-481 (2003).
25. Aho, T.L. et al. Pim1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett. 571, 43-49 (2004).
26. Lilly, M., Sandholm, J., Cooper, J.J., Koskinen, P.J. & Kraft, A. The PIM1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a BCL-2-dependent pathway. Oncogene 18, 4022-4031 (1999).
27. Juin, P., Geneste, O., Gautier, F., Depil, S. & Campone, M. Decoding and unlocking the BCL-2 dependency of cancer cells. Nat. Rev. Cancer 13, 455-465 (2013).
28. Montero, J. et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 160, 977-989 (2015).
29. Verbeek, S. et al. Mice bearing the Eμ-Myc and Eμ-Pim1 transgenes develop pre-B-cell leukemia prenatally. Mol. Cell. Biol. 11, 1176-1179 (1991).
30. Zippo, A., De Robertis, A., Serafni, R. & Oliviero, S. PIM1-dependent phosphorylation of histone H3 at Ser10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat. Cell Biol. 9, 932-944 (2007).
31. Sears, R. et al. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 14, 2501-2514 (2000).
32. Noguchi, K. et al. Regulation of c-Myc through phosphorylation at Ser-62 and Ser-71 by c-Jun N-terminal kinase. J. Biol. Chem. 274, 32580-32587 (1999).
33. Wang, X. et al. Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. Cancer Res. 71, 925-936 (2011).
34. Chandriani, S. et al. A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response. PLoS One 4, e6693 (2009).
35. Horiuchi, D. et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J. Exp. Med. 209, 679-696 (2012).
36. Grigoriadis, A. et al. Molecular characterization of cell line models for triple-negative breast cancers. BMC Genomics 13, 619 (2012).
37. Morishita, D., Katayama, R., Sekimizu, K., Tsuruo, T. & Fujita, N. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res. 68, 5076-5085 (2008).
38. Miura, K. et al. Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular-signal-regulated kinase. Oncogene 32, 5292-5301 (2013).
39. Hudis, C.A. & Gianni, L. Triple-negative breast cancer: an unmet medical need. Oncologist 16 (Suppl. 1), 1-11 (2011).
40. Kirschner, A.N. et al. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer. J. Natl. Cancer Inst. 107, dju407 (2014).
41. Turner, N.C. & Reis-Filho, J.S. Tackling the diversity of triple-negative breast cancer. Clin. Cancer Res. 19, 6380-6388 (2013).
42. Morton, J.P. & Sansom, O.J. MYC-y mice: from tumor initiation to therapeutic targeting of endogenous MYC. Mol. Oncol. 7, 248-258 (2013).
43. Horiuchi, D. et al. PIM kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Nat. Med. http://dx.doi.org/10.1038/nm.4213 (2016).
44. Petrocca, F. et al. A genome-wide siRNA screen identifes proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells. Cancer Cell 24, 182-196 (2013).
45. Garcia, P.D. et al. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers. Clin. Cancer Res. 20, 1834-1845 (2014).
46. Malinen, M. et al. Proto-oncogene PIM1 is a novel estrogen receptor target associating with high-grade breast tumors. Mol. Cell. Endocrinol. 365, 270-276 (2013).
47. Raab, M.S. et al. Phase 1 study of the novel pan-PIM kinase inhibitor LGH447 in patients with relapsed or refractory multiple myeloma. in 55th ASH Annual meeting and exposition (New Orleans, LA, 2013).
48. McEachern, K.A. et al. Preclinical and clinical pharmacodynamics of pan-PIM inhibition by AZD1208 in acute myeloid leukemia: assessment of PIM isoform dependency for BAD and 4EBP1 phosphorylation. in 56th ASH Annual meeting and exposition (San Francisco, CA, 2014).
49. Mori, S. et al. Utilization of pathway signatures to reveal distinct types of B lymphoma in the Eμ-myc model and human diffuse large-B-cell lymphoma. Cancer Res. 68, 8525-8534 (2008).
50. Bild, A.H. et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353-357 (2006).
51. Zeller, K.I., Jegga, A.G., Aronow, B.J., O'Donnell, K.A. & Dang, C.V. An integrated database of genes responsive to the Myc oncogenic transcription factor: identifcation of direct genomic targets. Genome Biol. 4, R69 (2003).
52. O'Donnell, K.A. et al. Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis. Mol. Cell. Biol. 26, 2373-2386 (2006).
53. Fernandez, P.C. et al. Genomic targets of the human c-Myc protein. Genes Dev. 17, 1115-1129 (2003).
54. Kim, Y.H. et al. Combined microarray analysis of small-cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplifcation. Oncogene 25, 130-138 (2006).
55. Lastowska, M. et al. Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J. Clin. Oncol. 19, 3080-3090 (2001).
56. Lee, J.S. et al. Application of comparative functional genomics to identify best-ft mouse models to study human cancer. Nat. Genet. 36, 1306-1311 (2004).
57. Menssen, A. & Hermeking, H. Characterization of the c-MYC-regulated transcriptome by SAGE: identifcation and analysis of c-MYC target genes. Proc. Natl. Acad. Sci. USA 99, 6274-6279 (2002).
58. Schlosser, I. et al. Dissection of transcriptional programs in response to serum and c-Myc in a human B cell line. Oncogene 24, 520-524 (2005).
59. Schuhmacher, M. et al. The transcriptional program of a human B cell line in response to Myc. Nucleic Acids Res. 29, 397-406 (2001).
60. Yu, D., Cozma, D., Park, A. & Thomas-Tikhonenko, A. Functional validation of genes implicated in lymphomagenesis: an in vivo selection assay using a Myc-induced B cell tumor. Ann. NY Acad. Sci. 1059, 145-159 (2005).
61. Hammond, M.E. et al. American Society of Clinical Oncology-College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28, 2784-2795 (2010).
62. Van Loo, P. et al. Allele-specifc copy-number analysis of tumors. Proc. Natl. Acad. Sci. USA 107, 16910-16915 (2010).
63. Rasmussen, M. et al. Allele-specifc copy-number analysis of tumor samples with aneuploidy and tumor heterogeneity. Genome Biol. 12, R108 (2011).
64. Meerbrey, K.L. et al. The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc. Natl. Acad. Sci. USA 108, 3665-3670 (2011).
65. Franken, N.A., Rodermond, H.M., Stap, J., Haveman, J. & van Bree, C. Clonogenic assay of cells in vitro. Nat. Protoc. 1, 2315-2319 (2006).